BR Malls Participações (OTCMKTS:BRMSY) versus SWEDISH ORPHAN/S (OTCMKTS:SWTUY) Head-To-Head Comparison

Risk and Volatility

BR Malls Participações has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, SWEDISH ORPHAN/S has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500.

Earnings & Valuation

This table compares BR Malls Participações and SWEDISH ORPHAN/S”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BR Malls Participações	$228.53 million	6.52	$34.65 million	$0.08	45.01
SWEDISH ORPHAN/S	$763.19 million	8.71	$134.73 million	$0.50	48.76

SWEDISH ORPHAN/S has higher revenue and earnings than BR Malls Participações. BR Malls Participações is trading at a lower price-to-earnings ratio than SWEDISH ORPHAN/S, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BR Malls Participações and SWEDISH ORPHAN/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BR Malls Participações	N/A	N/A	N/A
SWEDISH ORPHAN/S	25.75%	29.63%	18.74%

Summary

SWEDISH ORPHAN/S beats BR Malls Participações on 9 of the 9 factors compared between the two stocks.

About BR Malls Participações

BR Malls Participações S.A. operates and manages shopping malls in Brazil. It also promotes and manages real estate enterprises; manages parking lot operations; and offers digital solutions to support shopping malls and retail companies. The company was founded in 1949 and is headquartered in Rio de Janeiro, Brazil. As of March 31, 2022, BR Malls Participações S.A. operates as a subsidiary of Aliansce Sonae Shopping Centers S.A.

About SWEDISH ORPHAN/S

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetic and lysosomal diseases. The company offers Elocta to treat haemophilia A; and Alprolix to treat haemophilia B. It also provides Orfadin for the treatment of hereditary tyrosinaemia type 1; and Kineret for the treatment of auto inflammatory condition, as well as Xiapex to treat Dupuytren's contracture and Peyronie's disease. In addition, the company manufactures drug substance for ReFacto AF; and develops BIVV001 and BIVV002 for the treatment of hemophilia. It operates in Sweden, the Middle East, North Africa, Russia, North America, other European countries, and internationally. The company has an agreement with Bioverativ for the development and commercialization of Elocta and Alprolix, as well as XTEN-programs. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.